BioNTech plans to make vaccines in shipping containers
These standardised factories could be quickly scaled up to expand capacity worldwide
AT THE HEART of its site in Marburg, Germany, BioNTech is putting the finishing touches on a new kind of factory. The drug company has spent eight months reworking its manufacturing processes to produce its mRNA covid-19 vaccine inside a set of standard shipping containers. By creating a modular approach to drug manufacturing, Ugur Sahin, BioNTech’s boss, says he aims to transform medicine production around the world.
This article appeared in the Science & technology section of the print edition under the headline “Cloning vaccine factories”
From the February 19th 2022 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Science & technology
Should you start lifting weights?
You’ll stay healthier for longer if you’re strong
Does melatonin work for jet lag?
It can help. But it depends where you’re going
Training AI models might not need enormous data centres
Eventually, models could be trained without any dedicated hardware at all
How the Gulf’s rulers want to harness the power of science
A stronger R&D base, they hope, will transform their countries’ economies. Will their plan work?
Cancer vaccines are showing promise at last
Trials are under way against skin, brain and lung tumours
New firefighting tech is being trialled in Sardinia’s ancient forests
It could sniff out blazes long before they spread out of control